Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Gamechanger-Deal am Horizont: Entscheidende Nachrichten in 2025 erwartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DHX9 | ISIN: DK0061802139 | Ticker-Symbol: 4AJ0
Tradegate
23.04.25
18:29 Uhr
19,580 Euro
-0,110
-0,56 %
Branche
Pharma
Aktienmarkt
STOXX Europe 600
1-Jahres-Chart
ALK-ABELLO A/S Chart 1 Jahr
5-Tage-Chart
ALK-ABELLO A/S 5-Tage-Chart
RealtimeGeldBriefZeit
19,57019,59011:26
19,57019,59011:26

Aktuelle News zur ALK-ABELLO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiALK Abello: ITULAZAX tree pollen tablet approved for treatment of children in Europe70ALK (ALKB.DC / OMX: ALK B) today announced that its European regulatory filing for ITULAZAX® (tree pollen sublingual allergy immunotherapy tablet) for treatment of young children and adolescents aged...
► Artikel lesen
03.04.ALK Abello: Grant of share-based long-term incentive instruments to members of the Board of Management and key employees1
13.03.ALK Abello: Annual General Meeting in ALK-Abelló A/S held on 13 March 20253
07.03.ALK Abello: ACARIZAX approved in Canada for treatment of young children260ALK (ALKB:DC / OMX: ALK B) today announced that Health Canada has approved ALK's ACARIZAX® tablet for use in children, aged five to 11, with house dust mite (HDM) allergy. ACARIZAX® is now indicated...
► Artikel lesen
04.03.ALK Abello: Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff3
27.02.ALK Abello: FDA approves ODACTRA for the treatment of house dust mite allergy in young children292ALK (ALKB:DC / OMX: ALK B) today announced that the US Food and Drug Administration (FDA) has approved ALK's ODACTRA® tablet for use in young children with house dust mite (HDM) allergy. ODACTRA®...
► Artikel lesen
21.02.ALK Abello: Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff3
ALK-ABELLO Aktie jetzt für 0€ handeln
19.02.ALK-Abelló projects 9%-13% revenue growth for 2025 driven by global tablet expansion1
19.02.ALK Abello: Annual General Meeting in ALK-Abelló A/S on 13 March 20252
19.02.ALK-Abello shares rise following 4Q earnings report5
19.02.ALK-Abelló A/S reports FY results3
19.02.ALK Abello: Annual report 2024: ALK delivers 15% sales growth with profits up 65%254ALK's (ALKB:DC / OMX: ALK B / AKBLF) Board of Directors has approved the 2024 annual report. Following a robust performance in Q4, full-year results were in line with the latest outlook and represent...
► Artikel lesen
12.02.ALK Abello: Invitation to the presentation of ALK's annual report 2024 on Wednesday, 19 February 20254
31.01.ALK-Abello stock jumps as Jefferies upgrades to 'buy' on growth prospects16
30.01.ALK Abello: ALK's house dust mite tablet (ACARIZAX) now recommended by NICE for use in the UK health system351ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX® for the treatment of persistent, moderate...
► Artikel lesen
06.01.ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Files for Approval of neffy in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S4
20.12.24ALK Abello: ALK - Financial calendar for the 2025 financial year2
18.12.24ALK Abello: Positive results advance peanut tablet to phase II development197ALK's peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses imminently....
► Artikel lesen
12.12.24ALK Abello: ACARIZAX approved in Europe for treatment of young children4
27.11.24ALK Abello: ALK's pivotal phase 3 trial in children published in reputable scientific journal1
Seite:  Weiter >>
32 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1